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Abstract 47 
 48 
Objectives. Platelets orchestrate the inflammatory activities of neutrophils, possibly 49 
contributing to pulmonary and myocardial damage during severe pneumococcal 50 
infection. This study tested the hypothesis that the pneumococcal toxin, pneumolysin 51 
(Ply), activates production of platelet-activating factor (PAF) and thromboxane A2 52 
(TxA2) by neutrophils, these bioactive lipids being potential mediators of 53 
neutrophil:platelet (NP) networking. 54 
Methods. The effects of recombinant Ply (10–80 ng.mL-1) on the production of PAF 55 
and TxA2 by isolated neutrophils were measured using ELISA procedures, and NP 56 
aggregation by flow cytometry. 57 
Results. Exposure of neutrophils to Ply induced production of PAF and, to a lesser 58 
extent, TxA2, achieving statistical significance at ≥20 ng.mL-1 of the toxin. In the case 59 
of NP interactions, Ply promoted heterotypic aggregation which was dependent on 60 
upregulation of P-selectin (CD62P) and activation of protease-activated receptor 1 61 
(PAR1), attaining statistical significance at ≥10 ng.mL-1   of the toxin, but did not 62 
involve either PAF or TxA2. 63 
Conclusion. Ply induces synthesis of PAF and TxA2, by human neutrophils, neither of 64 
which appears to contribute to the formation of NP heterotypic aggregates in vitro, a 65 
process which is seemingly dependent on CD62P and PAR1. These pro-66 
inflammatory activities of Ply may contribute to the pathogenesis of pulmonary and 67 
myocardial injury during severe pneumococcal infection. 68 
 69 
Keywords. Calcium, platelet-activating factor, pneumolysin, P-selectin (CD62P), 70 
severe pneumococcal disease. 71 
 72 
 73 
  74 
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Pneumolysin (Ply), the cholesterol-binding, pore-forming toxin of Streptococcus 75 
pneumoniae, is recognised as being the major protein virulence factor of this 76 
intransigent respiratory pathogen, the most common bacterial cause of community-77 
acquired pneumonia (CAP) and associated organ damage (1-4). Importantly, Ply has 78 
been identified as being a key mediator of both acute lung injury (ALI) (5-8) and 79 
myocardial damage (9, 10) in murine models of severe pneumococcal disease. In 80 
one such model of ALI, exposure of isolated, perfused lungs to recombinant Ply 81 
resulted in the development of pulmonary hypertension and microvascular barrier 82 
dysfunction, both of which are key features of this condition in humans (6, 7). The 83 
underlying mechanisms appeared to involve increased pulmonary production of the 84 
bioactive lipid, platelet-activating factor (PAF), which, in turn, was proposed to 85 
activate production of the more potent platelet activator viz. the prostanoid, 86 
thromboxane A2 (TxA2), with resultant vasoconstriction and platelet activation (7). 87 
Although the authors speculated that PAF may have originated from Ply-exposed 88 
endothelial cells (7), infiltrating neutrophils represent an alternative source of the 89 
bioactive lipid. Unlike macrophages, neutrophils express high levels of the PAF-90 
generating enzyme, PAF acetylhydrolase (11). However, to our knowledge a 91 
possible link between Ply, neutrophils, PAF and platelet activation has not been 92 
described. 93 
            In the context of acute cardiovascular events associated with invasive 94 
pneumococcal disease, Ply, via its pore-forming activity, has been reported to inflict 95 
injury on myocardium through the formation of cardiac microlesions (9, 10). 96 
However, the existence of alternative mechanisms of Ply-mediated cardiotoxicity, 97 
possibly related to the pro-inflammatory/pro-thrombotic activities of the toxin are 98 
largely unexplored (12-14). 99 
 100 
 To probe the existence of such mechanisms in the pathogenesis of Ply-101 
mediated ALI and myocardial injury, we have investigated the effects of recombinant 102 
Ply on the production of PAF and TxA2 by isolated, human blood neutrophils in vitro. 103 
In addition, we have also explored the effects of Ply on the formation of potentially, 104 
pro-thrombotic, heterotypic aggregates of neutrophils and platelets (15-19), focusing 105 
on the involvement of PAF, TxA2 and other potent platelet activators, as well as the 106 
adhesion molecule, P-selectin (CD62P), in this process.  107 
 108 
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MATERIALS AND METHODS 109 
 110 
Permission to draw blood from healthy, adult human volunteers was granted by the 111 
Research Ethics Committee, Faculty of Health Sciences, University of Pretoria. 112 
 113 
Pneumolysin 114 
 115 
Recombinant Ply and the pneumolysoid, delta6Ply, attenuated in respect of 116 
pore-forming activity, were prepared as described previously (20, 21). The possible 117 
influence of contaminating endotoxin was excluded in both Ply preparations using 118 
the Endosafe®-PTS™ system (Charles River Laboratories, Wilmington, MA, USA) 119 
which is based on the Limulus amoebocyte lysate kinetic chromogenic method. Both 120 
active Ply and delta6Ply contained <1 endotoxin unit (EU)/µg of protein after 121 
purification (1 EU is the lower limit of detection). 122 
 123 
Chemicals 124 
 125 
PSB 0739, WEB 2086, S 18886 and SCH 79797 antagonists of the platelet 126 
purinergic receptor, P2Y12, the PAF receptor, the TxA2 TP prostanoid receptor, and 127 
the protease-activated receptor 1 (PAR1, thrombin activated) respectively were 128 
purchased from TOCRIS Bioscience, Bristol, UK. The oral thrombin inhibitor, 129 
dabigatran, was provided to one of us (GAR) by Boehringer-Ingelheim Pharma 130 
GmbH, Germany. All of these were dissolved to stock solutions of 10 mM in 131 
dimethylsulphoxide (DMSO) and used at final concentrations of 10 µM (final DMSO 132 
concentrations of 0.1%) in the assays described below. Appropriate DMSO control 133 
systems were included in all of the assays in which these receptor antagonists were 134 
used. 135 
 136 
 Mouse anti-human C62P blocking antibody (P-selectin, non-fluorochrome-137 
labelled), was purchased from Biolegend, London, UK. Unless stated, all other 138 
chemicals and reagents were purchased from the Sigma Chemical Co., St. Louis, 139 
MO, USA. 140 
 141 
 142 
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Preparation of neutrophils 143 
 144 
Neutrophils were prepared from heparinised venous blood (5 units 145 
preservative-free heparin.mL-1) as described previously (22). Briefly, 146 
neutrophil/erythrocyte pellets obtained following centrifugation of whole blood on 147 
Histopaque-1077 (Sigma Diagnostics) were resuspended and sedimented in 3% 148 
gelatin to remove most of the erythrocytes. Residual erythrocytes were then 149 
removed by differential lysis (brief treatment with 0.83% ammonium chloride) and the 150 
resultant neutrophil populations of high purity and viability (>90% and >95% 151 
respectively) suspended to a concentration of 1x107 cells.mL-1 in Hanks’ balanced 152 
salt solution (HBSS, indicator-free, pH7.4). 153 
 154 
PAF and TxA2 155 
 156 
Neutrophils (2x106) suspended in HBSS were prewarmed for 10 min at 37°C 157 
followed by addition of one of the following: i) HBSS (negative control); ii) 158 
recombinant Ply at final concentrations of 10, 20, 40 and 80 nanograms (ng).mL-1; iii) 159 
the pneumolysoid, delta6Ply, which is attenuated with respect to pore-forming 160 
activity, at a fixed, final concentration of 80 ng.mL-1; or iv) the calcium ionophore, 161 
A23187 at 2 µM (final) as a positive control system. The final volume in each test 162 
tube was 2 mL. After a further 5 min period of incubation at 37°C, the tubes were 163 
transferred to an ice-bath to stop the reactions. Following removal of the cells by 164 
centrifugation, the concentrations of PAF and TxA2 in the cell-free supernatants were 165 
measured using commercial sandwich ELISA procedures (Cusabio® Life Science, 166 
Wuhan, P.R. China and Abnova GmbH, Heidelberg, Germany respectively) and the 167 
results expressed as ng.mL-1 and picograms (pg).mL-1 respectively. Cell viability was 168 
measured using a propidium iodide-based flow cytometric procedure. 169 
 170 
Neutrophil:platelet (NP) aggregate formation 171 
 172 
In order to minimise spontaneous activation of platelets, NP-enriched buffy 173 
coat suspensions, enumerated for both cell types by standard haematological 174 
procedures, were used for these studies in keeping with earlier reports which used 175 
whole blood (23-25). These cell suspensions were prepared from the heparinised 176 
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blood of healthy, adult humans by sedimentation at 37°C and diluted 1:50 in HBSS 177 
to give a final volume of 1 ml. Following 5 min of preincubation at 37°C, recombinant 178 
Ply (10–80 ng.mL-1), delta6Ply (80 ng.mL-1), or adenosine 5’-diphosphate (ADP, 100 179 
µM final, agonist of platelet P2Y12 receptors as a positive control) were added to the 180 
cell suspensions which were incubated for a further 5 min at 37°C. Following 181 
incubation, the cell suspensions were stained with 5 µl of each of the following 182 
murine, anti-human, fluorochrome-labelled monoclonal antibodies to detect 183 
neutrophils, platelets and total leukocytes: CD16-allophyocyanin (Biolegend, San 184 
Diego, CA, USA), CD42a-phycoerythrin (Becton Dickenson, San Jose, CA, USA) 185 
and CD45-Krome Orange (Beckman Coulter, Marseille, France) and incubated for 186 
15 min at room temperature in the dark. This was followed by analysis of the various 187 
cell suspensions at a slow flow rate using a Gallios flow cytometer (Beckman 188 
Coulter, Miami, USA). NP interactions were determined according to the 189 
CD16+/CD42a+ co-expression profiles of CD45+ leukocytes and the results 190 
expressed as the relative median fluorescence intensities of CD42a expression of 191 
these NP aggregates . Platelet aggregates were excluded prior to the 192 
aforementioned analysis as indicated in Figure 1 which depicts this gating strategy. 193 
Note that residual erythrocytes [confirmed by staining with an anti-CD 235a 194 
(glycophorin) monoclonal antibody, Becton Dickenson] in the cell suspensions were 195 
not lysed prior to flow cytometric analysis to minimise non-specific activation of 196 
platelets. 197 
 198 
 In a limited series of experiments (2 in the series) undertaken to ensure the 199 
veracity of the various antagonists of platelet P2Y12 and PAF receptors and PAR1 200 
(PSB 0739, WEB 2086, and SCH 79797 respectively), these agents were added to 201 
platelet-rich plasma which was incubated for 5 min at 37ºC prior to the addition of the 202 
respective receptor agonists, ADP (100 µM), PAF (400 nM), or thrombin (from 203 
human plasma, 1.25 NIH units, final). After a further period of incubation for 5 min at 204 
37ºC platelet activation was measured flow cytometrically as described previously 205 
according to upregulated expression of the adhesion molecule, CD62P (P-selectin) 206 
(14, 25).  207 
 208 
The following series of experiments explored the effects of the various platelet 209 
receptor (P2Y12, PAF, PAR1, TxA2) antagonists (all at 10 µM), as well as those of 210 
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indomethacin (5 µM) and a mouse anti-human CD62 P blocking monoclonal 211 
antibody (5 µL per mL of cell suspension),	all added prior to preincubation, on NP 212 
aggregation activated by Ply (40 ng.mL-1, final) measured as described above. The 213 
following were also investigated: i) the requirement for extracellular Ca2+ in the pro-214 
aggregation activity of Ply; ii) the specificity of the PAR1 receptor antagonist, SCH 215 
79797, which was assessed by measuring the effects of this agent on NP 216 
aggregation induced by purified thrombin (1.25 NIH units), as well as on 217 
spontaneous aggregation and that activated by ADP (100 µM); and iii) the effects of 218 
dabigatran (10 µM) on NP aggregation induced by either thrombin or Ply (40 ng.mL-219 
1
, final)  220 
       221 
           222 
Expression and statistical analysis of results 223 
 224 
The results of each series of experiments are expressed as median values 225 
with interquartile ranges with numbers of different donors and experiments indicated 226 
in the text or figure legends. Statistical analyses were performed using GraphPad 227 
Prism5 (GraphPad Software, San Diego, USA) using a one-way ANOVA with a 228 
Bonferroni correction for multiple comparisons.  229 
 230 
 231 
RESULTS 232 
 233 
Production of PAF and TxA2 by Ply-activated neutrophils 234 
 235 
These results are shown in figures 2A and 2B for PAF and TxA2 respectively. 236 
As shown in figure 2A, exposure of neutrophils to Ply resulted in dose-related 237 
activation of generation of PAF which achieved statistical significance at 238 
concentrations ≥20ng.mL-1 of the toxin, while the non-physiological positive control, 239 
A23187, as expected was extremely potent, and delta6Ply ineffective. The 240 
corresponding data for TxA2 production by neutrophils are shown in figure 2B, which 241 
demonstrate similar, albeit lesser, effects. 242 
 243 
 244 
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Neutrophil viability 245 
 246 
 These results are shown in Figure 3. Exposure of neutrophils to the highest 247 
concentrations of Ply (40 and 80 ng.mL-1) or to A23187 caused modest, but 248 
nevertheless statistically significant, loss of viability. The median viability values for 249 
the control, untreated system and for systems treated with Ply at 40 and 80 ng.mL-1 250 
or A23187 were 98.9% (IQR 98.5-99.4%), 93.9% ( p<0,005), 91.0% ( p<0,001), and 251 
95.4% ( p<0.01) respectively (data from 4 experiments using cells from 4 different 252 
donors). 253 
 254 
 255 
Effect of Ply on the formation of NP heterotypic aggregates 256 
 257 
The median neutrophil and platelet counts of the buffy coats used in these 258 
and subsequent experiments were 4.67 x 103.µL-1 and 451 x 10-3.µL-1 respectively, 259 
and the results are shown in Figure 3. Addition of Ply to mixed NP suspensions 260 
resulted in dose-related formation of NP aggregates which achieved statistical 261 
significance at concentrations of ≥20 ng.mL-1 of the toxin and was greater than that 262 
observed with ADP, while delta6Ply was ineffective (Figure 4). 263 
 264 
Assessment of the veracity of the various platelet receptor antagonists 265 
 266 
 Prior to assessing their effects on Ply-mediated NP aggregate formation, the 267 
efficacy of the various platelet-receptor antagonists (PSB 0739,WEB 2086, SCH 268 
79797, all at 10 µM) was measured in a series of preliminary experiments, using 269 
platelet-rich plasma. Following addition of the corresponding, respective receptor 270 
agonists ADP (100 µM), PAF (400 nM) or thrombin (1.25 NIH units), platelet 271 
activation was measured flow cytometrically according to the level of expression of 272 
the adhesion molecule, CD62P. The results, which are shown in Figure 5, 273 
demonstrate the activities of the receptor agonists, with PAF being the least potent, 274 
as well as the inhibitory activities of the various receptor antagonists. Importantly, 275 
upregulation of expression of CD62P by ADP-, PAF- or thrombin-treated platelets 276 
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was significantly attenuated by PSB 0739, WEB 2086, and SCH 79797, confirming 277 
receptor antagonism. 278 
 279 
Effects of the various platelet receptor antagonists, indomethacin, 280 
Ca2+depletion, and an anti-CD62P monoclonal antibody on Ply-mediated NP 281 
aggregation   282 
 283 
         The effects of the various platelet receptor antagonists and indomethacin, as 284 
well as those of suspension of the cells in Ca2+-free HBSS, on Ply (40 ng.mL-1)-285 
activated formation of NP aggregates are shown in Figure 6A, while those of 286 
inclusion of the anti-human CD62P blocking monoclonal antibody are shown in 287 
Figure 6B.  Exposure of the cells to the PAR1 antagonist, SCH 79797, as well as 288 
suspension of the cells in Ca2+-free medium resulted in significant attenuation of Ply-289 
activated formation of NP aggregates, while the other receptor antagonists and 290 
indomethacin were ineffective (Figure 6A). Inclusion of the anti-CD62P antibody 291 
caused almost complete attenuation of Ply-mediated NP aggregate formation (Figure 292 
6B).  Depletion of Ca2+, as well as inclusion of the anti-CD62P antibody also caused 293 
significant reductions in basal NP aggregation, underscoring the involvement of both 294 
Ca2+ and CD62P in basal aggregation. These observations demonstrate significant 295 
involvement of CD62P, as well as PAR1, but not the P2Y12, PAF or TxA2 receptors 296 
in Ply-mediated NP aggregate formation.  297 
 298 
Effects of SCH 79797 on spontaneous, ADP- and thrombin-activated NP 299 
aggregation 300 
 301 
         To probe the receptor-targeted veracity of SCH 79797 (10µM) in the context of 302 
NP aggregate formation, the effects of this agent on spontaneous, ADP- or thrombin-303 
activated NP aggregation were investigated and these results are shown in Figure 7. 304 
Addition of SCH 79797 to the mixed neutrophil and platelet suspensions during pre -305 
incubation resulted in statistically significant formation of thrombin-activated 306 
heterotypic aggregates, but had no effect on either spontaneous or ADP-activated 307 
formation of NP aggregates. These findings confirm the selectivity of SCH 79797 for 308 
PAR1 and the probable involvement of this receptor in Ply-mediated NP aggregate 309 
formation, possibly via thrombin activation. 310 
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Effect of dabigatran on Ply-mediated NP aggregation 311 
 312 
         The thrombin inhibitor, dabigatran, was used to explore the possible 313 
involvement of thrombin in Ply-mediated activation of PAR1 and these results are 314 
shown in Figure 8. Dabigatran was found to attenuate thrombin-, but not Ply-315 
mediated formation of NP aggregates, apparently excluding the involvement of 316 
thrombin derived from either the plasma or cellular elements of the buffy coat 317 
preparations in Ply-activated NP aggregation. 318 
 319 
Effect of SCH 79797 on the pore-forming activity of Ply 320 
 321 
An erythrocyte haemolysis assay was used to exclude possible interference of 322 
SCH 79797 with the pore-forming activity of Ply. Erythrocytes are particularly 323 
vulnerable to the lytic action of Ply. Briefly, the toxin (20 ng.mL-1) was pre-incubated 324 
with SCH 79797 (10 µM) for 5 min at 37ºC followed by the addition of a 0.5% 325 
suspension of human erythrocytes in a final volume of 1 mL HBSS. Following 5 min 326 
incubation, the remaining erythrocytes were pelleted by centrifugation and 327 
haemoglobin in the supernatant fluids measured spectrophotometrically at a 328 
wavelength of 490 nm. The mean percentages haemolysis of Ply-treated 329 
erythrocytes in the absence or presence of SCH 79797 were 24% and 25% 330 
respectively (NS), clearly indicating lack of interference of the PAR1 antagonist with 331 
the pore-forming activity of Ply.  332 
 333 
 334 
   335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
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DISCUSSION 345 
 346 
The results of the current study demonstrate that exposure of neutrophils to 347 
Ply, at concentrations representative of those measured in the cerebrospinal fluid of 348 
patients with pneumococcal meningitis (26), caused dose-related generation of 349 
production of PAF, reaching levels which were about 3-fold higher than those of the 350 
untreated control system at the highest concentrations tested (40 and 80 ng.mL-1). 351 
The pneumolysoid, delta6Ply, was ineffective, while the calcium ionophore, A23187, 352 
included as a positive control system, was more potent than Ply. Similar, but less 353 
impressive trends were observed in the case of TxA2, possibly indicative of intense 354 
competition for arachidonic acid by the range of prostanoid/eicosanoid/PAF-355 
generating enzymes present in activated neutrophils. Although not shown, similar 356 
effects were observed with TxB2, excluding conversion of TxA2 to TxB2 as a possible 357 
cause of the lesser effect of Ply on production of TxA2 by neutrophils relative to PAF.  358 
Although exposure of neutrophils to the toxin at concentrations of 40 and 80 ng.mL-1 359 
resulted in loss of viability, these effects were modest and unlikely to have 360 
contributed to the observed activation of production of PAF and TxA2. In this context, 361 
it is noteworthy that some types of mammalian cell can withstand the cytotoxic 362 
actions of Ply due to the existence of a mechanism which promotes microvesicle 363 
shedding of toxin pores (27). Ply-mediated pore formation in the plasma membrane 364 
of inflammatory cells does, however, result in an influx of extracellular Ca2+ which 365 
either activates or sensitises the cells for increased pro-inflammatory activity (12-14). 366 
 367 
 A possible association between the production of PAF and TxA2 by Ply-368 
treated neutrophils and activation of neighbouring platelets was explored by 369 
investigating the effects of the toxin on the heterotypic aggregation of these cells in 370 
the absence and presence of a PAF or TP receptor antagonist, as well as 371 
antagonists of other types of receptor which mediate platelet activation, these being 372 
P2Y12 and PAR1. Exposure of mixed NP suspensions to Ply resulted in significant 373 
dose-related heterotypic aggregation of these cells which was maximal at 40-80 374 
ng.mL-1 of the toxin, exceeding that observed with ADP, and dependent on the 375 
presence of extracellular Ca2+, while delta6Ply was ineffective. With respect to the 376 
effects of the various receptor antagonists, only SCH 79797, somewhat surprisingly, 377 
was found to attenuate Ply-mediated NP heterotypic aggregation, while blockade of 378 
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the PAF, P2Y12, and TP receptors, as well as inhibition of cyclooxygenases with 379 
indomethacin, were all ineffective. The selectivity of SCH 79797 for the PAR1 was 380 
confirmed by the absence of effects of this agent on either spontaneous or ADP-381 
activated NP aggregation. In addition, SCH 79797 did not interfere with the pore-382 
forming activity of Ply, excluding non-specific inactivation of the toxin as a possible 383 
mechanism of interference with NP aggregation. In this context it is noteworthy that 384 
antagonism of PAR1 has recently been reported to decrease the levels of 385 
pulmonary, pro-inflammatory cytokines/chemokines and to attenuate alveolar leak in 386 
a murine model of  experimental pneumococcal pneumonia (28).  387 
 388 
The apparent involvement of triggering of PAR1 on platelets in NP heterotypic 389 
aggregation was an unexpected finding, which is most likely a secondary, albeit 390 
important, amplification mechanism resulting from interaction of the receptor with 391 
putative activators derived from Ply-activated platelets and/or neutrophils, reinforcing 392 
and sustaining NP adhesion. Possible contenders include  prothrombin released 393 
from platelet α-granules (29), which may be converted to thrombin by the action of 394 
pro-thrombinase expressed on neighbouring monocytes (30). Activation of PAR4 395 
which is also expressed on platelets and activated by thrombin, albeit at a slower 396 
rate than PAR1, may also contribute to NP aggregation (31). However, the lack of an 397 
effect of the thrombin inhibitor, dabigatran, on Ply-mediated NP aggregation appears 398 
to exclude any meaningful involvement of thrombin activation of PARs.  An 399 
alternative, albeit unexplored mechanism, implicates the serine proteinases, elastase 400 
and proteinase 3, as well as the matrix metalloproteinases 8 and 9 expressed by Ply-401 
exposed adherent neutrophils (13, 32) all of which are known activators of PAR 1 402 
(33, 34), while cathepsin G has been reported to activate PAR 4  (35). Addressing 403 
this issue is, however, beyond the scope of the current study given the spectrum of 404 
neutrophil-derived proteinases and their probable interactions, compounded by the 405 
requisite large number of enzyme inhibitors. 406 
 407 
 408 
 Together with the observation that inclusion of an anti-CD62P monoclonal 409 
antibody caused  almost complete attenuation of Ply-mediated NP aggregate 410 
formation, the aforementioned observations appear to be consistent with a sequence 411 
of events whereby exposure of platelets to Ply results in influx of extracellular Ca2+, 412 
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as described previously (14),  Ca2+-dependent mobilisation of  α-granules, 413 
upregulated surface expression of CD62P, and adhesion of neighbouring 414 
neutrophils. In this context, interactions between CD62P expressed on platelets and 415 
its counter ligand, P-selectin glycoprotein ligand-1 (PSGL-1) expressed on platelets 416 
and other cell types, are considered to be the primary mediators of platelet 417 
homotypic and heterotypic aggregation (15, 17, 24, 36). Although platelet-derived 418 
CD40 ligand has also been reported to mediate this type of interaction, the results of 419 
the current study appear to implicate CD62P as being the major player in the pro-420 
adhesive actions of Ply (37, 38). Although speculative, initial CD62P-dependent NP 421 
adhesion is then reinforced by neutrophil proteinase-mediated activation of platelet 422 
PAR1, resulting in the formation of more stable NP aggregates. Given that 423 
endothelial cells also express PAR1 (39), it is likely, albeit unexplored that exposure 424 
of endothelium to Ply also results in Ca2+ influx and upregulation of endothelial 425 
CD62P. This, in turn, may promote the binding of neutrophils and NP aggregates 426 
favouring activation of endothelial PAR1 and endothelial dysfunction (39). 427 
       428 
   429 
 In agreement with the findings of the current study, CD62P-dependent 430 
formation of NP aggregates following exposure of whole blood to the bacterial pore-431 
forming toxins, streptolysin-O or Staphylococcus aureus α-hemolysin, has been 432 
described previously (23, 24). In the case of the former, the authors proposed a link 433 
between streptolysin-O production, formation of NP aggregates, and vascular 434 
occlusions and tissue damage during infection with group A streptococci (23). In the 435 
case of α-hemolysin, heterotypic aggregate formation was linked to alveolar capillary 436 
destruction in haemorrhagic/necrotising pneumonia caused by community-437 
associated, methicillin-resistant S. aureus (24). However, unlike the current study, 438 
neither of these earlier studies, investigated the pathophysiological mechanisms 439 
underpinning toxin-mediated aggregate formation. Very recently, Zhang et al. in a 440 
study focused primarily on the S. suis pore-forming toxin, suilysin, reported that this 441 
toxin, as well as Ply, promoted NP aggregation in vitro by a Ca2+- and P-selectin-442 
dependent mechanism as described in the current study (40). However, in the study 443 
reported by Zhang et al.  Ply was used at a concentration considerably higher (800 444 
ng.mL-1 , fixed) than those used in the current study (10-80 ng.mL-1), while these 445 
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authors did not investigate the involvement of platelet-activating receptors in either 446 
suilysin- or Ply-mediated NP aggregation (40) 447 
 448 
While the exact clinical significance of the findings of the current study await 449 
clarification, they do, however, imply a multifaceted role for Ply in the pathogenesis 450 
of lung, heart and other types of organ damage during severe pneumococcal 451 
disease. Notwithstanding direct Ply-mediated organ damage (6-10), the effects of the 452 
toxin described here are also consistent with a pathogenic role for Ply-mediated 453 
formation of large, intravascular NP aggregates with resultant microvascular 454 
occlusion. Importantly, activated platelets and NP aggregates may also promote  455 
tissue injury by amplifying the inflammatory response.  On a cautionary note, 456 
however, should these harmful activities of the toxin be evident in the clinical setting, 457 
therapeutic targeting may prove difficult given the drawbacks and side effect profile 458 
of a commercially available PAR1 antagonist, vorapaxar (41), as well as the current 459 
lack of pharmacological agents which directly inhibit Ply. In this context, inhibitors of 460 
bacterial protein synthesis, especially macrolide antibiotics, may offer the best 461 
therapeutic option (42). 462 
 463 
  464 
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Figure legends: 611 
Figure 1.  612 
Illustration of the gating strategy followed to identify platelet:neutrophil aggregates. 613 
Large aggregates were excluded using a Forward Scatter Area vs Forward Scatter 614 
Height plot. This was followed by the identification of CD45+ leukocytes, after which 615 
CD16+ neutrophils were identified. The expression intensity of CD42a (marker for 616 
platelets) was then measured on the CD45+/CD16+/CD42a+ cells. An erythrocyte 617 
lysis step was not included in order to minimise non-specific activation of platelets. 618 
 619 
Figure 2. 620 
 The effects of addition of pneumolysin (Ply) at concentrations of 10-80 ng.ml-1, as 621 
well as those of delta 6 pneumolysin (delta6Ply, 80ng.ml-1) and the calcium 622 
ionophore A23187 (2 µM), to neutrophils on the production of platelet-activating 623 
factor (PAF) and thromboxane A2 (TxA2)  are shown in figures 2A and 2B 624 
respectively. The data from 5 different experiments, using cells from 5 different 625 
individuals, are expressed as the median values with interquartile ranges. 626 
BG=background value for unstimulated cells. 627 
*p<0.05-p<0.002 628 
Figure 3. 629 
The effects of the addition of pneumolysin (Ply), at concentrations of 5-80 ng.ml-1, as 630 
well as those of delta 6 pneumolysin (delta6Ply, 80ng.ml-1) and the calcium 631 
ionophore A23187 (2 µM, positive control) on neutrophil viability. 632 
*p<0.01-p<0.001 633 
Figure 4. 634 
The effects of the addition of ADP (100 µM, positive control) or pneumolysin (Ply, 10-635 
80 ng.ml-1) or delta 6 pneumolysin (delta6Ply 80 ng.ml-1) on the formation of 636 
heterotypic neutrophil:platelet (NP) aggregates. The results of 35 experiments, using 637 
cell suspensions from 13 different donors are expressed as the CD42a median 638 
fluorescence intensity (MFI) with interquartile ranges. The aggregates assessed 639 
were positive for co-expression of CD16, CD42a and CD45. 640 
*p<0.001-p<0.0001 641 
 642 
 643 
 644 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
Figure 5. 645 
The effects of addition of ADP (100 µM), platelet-activating factor (PAF, 400 nM) or 646 
thrombin (1.25 NIH units.ml-1) in the absence and presence of their respective 647 
receptor antagonists (PSB 0739, WEB 2086, SCH 79797 all at 10 µM) to platelet-rich 648 
plasma on expression levels of the adhesion molecule CD62P. The results of 6 649 
experiments, using platelet rich plasma from 2 different donors are expressed as the 650 
median CD16+/CD42a+/CD45+ fluorescence intensities with interquartile ranges.  651 
 652 
Figure 6. 653 
The results in the upper figure (5A) show the effects of pneumolysin (Ply 40 ng.ml-1 ) 654 
only or in the presence of WEB 20186, SCH 79797, indomethacin, PSB 0739 or S 655 
18886, all at 10 µM), as well as the effect of calcium depletion from the cell 656 
suspending medium, on the formation of neutrophil;platelet (NP) heterotypic 657 
aggregates. The results of 18 experiments using cells from 7 donors are expressed 658 
as the median CD16+/CD42a+/CD45+ fluorescence intensities with interquartile 659 
ranges. 660 
The results in the lower figure (5B) show the effects of addition of an anti-CD62P 661 
monoclonal antibody to buffy coat suspensions on the spontaneous (BG) and 662 
pneumolysin (Ply 40 ng.ml-1)-activated formation of neutrophil:platelet heterotypic 663 
aggregates. 664 
*p<0.006 For comparison with the corresponding Ply-treated, drug-free control 665 
system. 666 
*p<0.0004 For comparison of the control and corresponding anti-CD62P-treated 667 
systems.  668 
 669 
Figure 7. 670 
Measurement of the effects of addition of the PAR1 receptor antagonist, SCH 79797 671 
(10 µM), to buffy coat suspensions on the spontaneous (background) and ADP 672 
(100µM)- or thrombin (1.25 NIH units.ml-1)-activated formation of neutrophil platelet 673 
(NP) heterotypic aggregates. The results of 4 experiments using cells from 4 donors 674 
are expressed as the CD42a median fluorescence intensity (MFI) with interquartile 675 
ranges. The aggregates assessed were positive for co-expression of CD16, CD42a 676 
and CD45. 677 
*p<0.001 For comparison of the thrombin-activated systems without and with SCH 678 
79797 679 
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 680 
 Figure 8. 681 
Measurement of the effects of dabigatran (10 µM) added to buffy coat suspensions 682 
on the formation of heterotypic neutrophil:platelet (NP) aggregates, activated by 683 
either thrombin (1.25 NIH units.ml-1) or pneumolysin (Ply 40 ng.ml-1). The results of 6 684 
experiments using cells from 2 donors are expressed as the median 685 
CD16+/CD42+/CD45+ fluorescence intensities with interquartile ranges. 686 
*p<0.02 For comparison of the thrombin-activated systems in the absence or 687 
presence of dabigatran. 688 
 689 
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Highlights 
 
• Pneumolysin (Ply) activates production of PAF and thromboxane A2 (TxA2) by 
neutrophils. 
 
• Ply also promotes formation of pro-thrombotic neutrophil:platelet (NP) 
aggregates. 
 
• Ply-mediated aggregate formation is independent of PAF and TxA2. 
 
• P-selectin (CD62P) and protease-activated receptor 1 are involved in Ply-induced 
NP aggregation. 
 
• Ply-mediated NP aggregate formation may contribute to pulmonary and 
myocardial injury. 
